Sökning: onr:"swepub:oai:DiVA.org:uu-91694" >
Streptozocin and o,...
Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients : long-term survival in its adjuvant use
-
- Khan, Tanweera Shaheena (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Imam, Hassan (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Juhlin, Claes (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper
-
visa fler...
-
- Skogseid, Britt (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Gröndal, Staffan (författare)
- Karolinska Institutet
-
Tibblin, Sten (författare)
-
- Wilander, Erik (författare)
- Uppsala universitet,Molekylär och morfologisk patologi
-
- Öberg, Kjell (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
- Eriksson, Barbro (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2000
- 2000
- Engelska.
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 11:10, s. 1281-1287
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND:To evaluate the efficacy of streptozocin and o.p'DDD (SO) in adrenocortical cancer (ACC) patients since other chemotherapeutic regimens have limited effects.PATIENTS AND METHODS:We performed a phase II study with SO therapy in 40 ACC patients (median age 44 years). Oral o,p'DDD administration (1-4 g/d, every day) was given together with intravenous streptozocin (1 g/d for five days, thereafter 2 g once every three weeks). 5HT3-receptor blocker was used as standard premedication for streptozocin.RESULTS:The SO therapy was found to have significant effects on disease-free interval (P = 0.02) as well as on survival (P = 0.01) in adjuvantly treated cases (n = 17) in comparison to the patients who did not get any therapy after complete resection (n = 11). Complete or partial response was obtained in 36.4% of patients with measurable disease (n = 22). The overall two-year and five-year survival rates were 70% and 32.5%, respectively. The presence of metastases at diagnosis was identified as a poor prognostic factor (P = 0.02).CONCLUSIONS:The present study necessitates further randomized clinical study of SO therapy in the treatment of ACC, mainly as adjuvant treatment immediately after curative intended surgery, and could be developed into a regular treatment regimen.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Oncology
- Onkologi
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas